Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | Chief Financial Officer | February 14, 2024 | February 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncternal Therapeutics, Inc.
Report date February 14, 2024 · Filed February 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $9.18 · Expires 2034-02-14 | Direct | 14,200 |
Reported balance
After 2024-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-14 · Grant · Acquired 14,200 · Balance 14,200 F1: 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forte Biosciences, Inc.
Report date August 27, 2026 · Filed August 27, 2026
Section 16 reporting ended · disclosed 2026-08-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2034-09-17 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2035-03-20 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-27 · Disposition to issuer · Disposed 31,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-27 · Disposition to issuer · Disposed 18,353 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 27, 2026 20:32 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Disposition to issuerRestricted Stock Units · Derivative | 18,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001269341-26-000003 · form4-08272026_080820.xml · derivative · entry 3 VINCENT RICHARD G · CIK 0001269341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,353 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. F4 · price: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. Read SEC document |
| August 27, 2026 Filed Aug 27, 2026 20:32 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Disposition to issuerStock Option (right to buy) · Derivative | 31,000 | Not disclosed Strike: $7.54 | Not disclosed |
DisclosureSEC source: 0001269341-26-000003 · form4-08272026_080820.xml · derivative · entry 2 VINCENT RICHARD G · CIK 0001269341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,000 shares Expires 2035-03-20 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · derivative.exercise_date: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Read SEC document |
| August 27, 2026 Filed Aug 27, 2026 20:32 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Disposition to issuerStock Option (right to buy) · Derivative | 2,000 | Not disclosed Strike: $7.07 | Not disclosed |
DisclosureSEC source: 0001269341-26-000003 · form4-08272026_080820.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2034-09-17 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · derivative.exercise_date: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:38 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantRestricted Stock Units · Derivative | 18,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001269341-26-000002 · form4-06022026_080621.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,353 Underlying: Common Stock · 18,353 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 20:50 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $7.54 | $0.00 |
DisclosureSEC source: 0001415889-25-008784 · form4-03212025_080302.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three (3) year period such that the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. "Date of Grant" shall mean March 20, 2025. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 22:30 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-24-023723 · form4-09192024_100907.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2034-09-17 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the thirty six (36) months following the Date of Grant, such that the shares subject to the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. "Date of Grant" shall mean September 17, 2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 23:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 14,200 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-24-003408 · doc4.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,200 Underlying: Common Stock · 14,200 shares Expires 2034-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Tax withholdingCommon Stock | 8,868 | $0.50 | $4,399.41 |
DisclosureSEC source: 0001209191-24-000972 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,922 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 210,000 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 12 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2033-02-21 F8 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 28,750 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 11 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 28,750 shares Expires 2032-07-28 F8 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F5 · derivative.exercise_date: 50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 109,597 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 10 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,597 Underlying: Common Stock · 109,597 shares Expires 2032-01-20 F8 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F4 · derivative.exercise_date: 25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 280,000 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 9 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2031-02-11 F7 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a "Qualifying Termination"); or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 25% of the Option Shares vested on February 11, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 35,120 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 8 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,120 Underlying: Common Stock · 35,120 shares Expires 2030-03-17 F7 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a "Qualifying Termination"); or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The shares subject to the option (the "Option Shares") are fully vested. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 75,000 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 7 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-09-12 F7 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a "Qualifying Termination"); or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The shares subject to the option (the "Option Shares") are fully vested. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 210,000 | Not disclosed Strike: $0.96 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 6 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 210,000 shares Expires 2033-02-21 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 28,750 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 5 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,750 shares Expires 2032-07-28 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F5 · derivative.exercise_date: 50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 109,579 | Not disclosed Strike: $1.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 4 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,579 shares Expires 2032-01-20 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F4 · derivative.exercise_date: 25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 280,000 | Not disclosed Strike: $7.05 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 3 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280,000 shares Expires 2031-02-11 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 25% of the Option Shares vested on February 11, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 35,120 | Not disclosed Strike: $3.33 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 2 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,120 shares Expires 2030-03-17 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The shares subject to the option (the "Option Shares") are fully vested. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 75,000 | Not disclosed Strike: $5.76 | Not disclosed |
DisclosureSEC source: 0001209191-23-052015 · doc4.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2029-09-12 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The shares subject to the option (the "Option Shares") are fully vested. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 22:58 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Tax withholdingCommon Stock | 7,069 | $0.36 | $2,544.84 |
DisclosureSEC source: 0001209191-23-041316 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,790 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 10:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 30,000 | $0.30 | $8,961.00 |
DisclosureSEC source: 0001209191-23-024263 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,859 F1 · price: The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $0.2975 to $0.3000. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 210,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001209191-23-012396 · doc4.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Tax withholdingCommon Stock | 4,428 | $1.02 | $4,516.56 |
DisclosureSEC source: 0001209191-23-002028 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,859 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 22:19 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 28,750 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-22-043736 · doc4.xml · derivative · entry 4 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 28,750 shares Expires 2032-07-28 F2 · derivative.exercise_date: One half of the shares subject to the stock options vest on July 3, 2023 and one half of the shares subject to the stock options vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the shares subject to the stock options vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 22:19 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantCommon Stock | 43,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043736 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,287 F1 · shares: Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on July 3, 2023, and one half of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 20:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 2,500 | $1.40 | $3,500.00 |
DisclosureSEC source: 0001209191-22-021302 · doc4.xml · nonDerivative · entry 5 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,162 Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 20:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 2,136 | $1.49 | $3,182.43 |
DisclosureSEC source: 0001209191-22-021302 · doc4.xml · nonDerivative · entry 4 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,662 Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 20:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 5 | $1.48 | $7.40 |
DisclosureSEC source: 0001209191-22-021302 · doc4.xml · nonDerivative · entry 3 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,526 Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 20:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 356 | $1.45 | $516.20 |
DisclosureSEC source: 0001209191-22-021302 · doc4.xml · nonDerivative · entry 2 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,521 Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 20:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 3 | $1.45 | $4.35 |
DisclosureSEC source: 0001209191-22-021302 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,165 Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 21:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 2,500 | $1.65 | $4,125.00 |
DisclosureSEC source: 0001209191-22-005559 · doc4.xml · nonDerivative · entry 3 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,162 Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 21:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 5,000 | $1.70 | $8,500.00 |
DisclosureSEC source: 0001209191-22-005559 · doc4.xml · nonDerivative · entry 2 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,662 Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 21:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 5,000 | $1.80 | $9,000.00 |
DisclosureSEC source: 0001209191-22-005559 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,662 Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 21:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 109,579 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001209191-22-004585 · doc4.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,579 Underlying: Common Stock · 109,579 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantCommon Stock | 29,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001971 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,662 F1 · shares: Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on January 3, 2023, one quarter of the RSUs vest on July 3, 2023, and one quarter of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 280,000 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001209191-21-010903 · doc4.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2031-02-11 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 22:49 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 35,120 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001209191-20-020092 · doc4.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,120 Underlying: Common Stock · 35,120 shares Expires 2030-03-17 F1 · derivative.exercise_date: Fully vested on grant date. Read SEC document |
| March 17, 2020 Filed Aug 1, 2020 01:05 UTC Amendment | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantCommon Stock · Derivative | 35,120 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001209191-20-044379 · doc4a.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,120 Underlying: Common Stock · 35,120 shares Expires 2030-03-17 F1 · shares: The original Form 4 reported the acquisition of the Stock Options in the "D" column of Column 5. This amendment is being filed to correctly report the acquisition of the Stock Options in the "A" column of Column 5. F2 · derivative.exercise_date: Fully vested on grant date. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 21:38 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0001209191-19-049689 · doc4.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-09-12 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date. Read SEC document |
| September 12, 2019 Filed Aug 1, 2020 01:05 UTC Amendment | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0001209191-20-044376 · doc4a.xml · derivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-09-12 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:34 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantWarrants · Derivative | 281 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0000899243-19-016481 · doc4.xml · derivative · entry 5 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust. Disclosed balance after: 281 Underlying: Common Stock · 281 shares Expires 2022-09-12 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share. F3 · derivative.exercise_date: The warrants are currently exercisable. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:34 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Options · Derivative | 73,385 | Not disclosed Strike: $0.81 | Not disclosed |
DisclosureSEC source: 0000899243-19-016481 · doc4.xml · derivative · entry 4 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,385 Underlying: Common Stock · 73,385 shares Expires 2028-11-14 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share. F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option will vest on November 7, 2019. The remainder of the shares subject to the option will vest in thirty-six equal montly installments beginning on December 7, 2019. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:34 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantCommon Stock | 1,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-016481 · doc4.xml · nonDerivative · entry 3 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By child. Disclosed balance after: 1,834 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:34 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantCommon Stock | 4,526 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-016481 · doc4.xml · nonDerivative · entry 2 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust. Disclosed balance after: 4,526 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:34 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantCommon Stock | 42,628 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-016481 · doc4.xml · nonDerivative · entry 1 VINCENT RICHARD G · CIK 0001269341 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,794 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.